Scribd Logo
Загрузить

Добро пожаловать в Scribd!

  • GSK Flu Vaccine Production Process

    Загружено:

    Ehab Tantawy
    623 просмотров1 страница
    The document describes the international surveillance network that monitors influenza viruses in humans and animals globally. It detects important antigenic variations that allow the WHO to propose recommendations for vaccine formulations each flu season. The WHO then distributes seed strains to manufacturers like GSK to begin the 5-6 month vaccine production process. This process involves inoculating eggs, harvesting and purifying the virus, testing, filling doses, clinical trials, and regulatory approval to produce an optimized vaccine that matches the current circulating strains each year. Adjuvants can increase the efficiency of vaccines by helping the body reach a protective antibody threshold faster than with antigen alone.

    Исходное описание:

    Авторское право

    © Attribution Non-Commercial (BY-NC)

    Доступные форматы

    PDF, TXT или читайте онлайн в Scribd

    Этот документ был вам полезен?

    Это неприемлемый материал?

    Пожаловаться на этот документ
    The document describes the international surveillance network that monitors influenza viruses in humans and animals globally. It detects important antigenic variations that allow the WHO to propose recommendations for vaccine formulations each flu season. The WHO then distributes seed strains to manufacturers like GSK to begin the 5-6 month vaccine production process. This process involves inoculating eggs, harvesting and purifying the virus, testing, filling doses, clinical trials, and regulatory approval to produce an optimized vaccine that matches the current circulating strains each year. Adjuvants can increase the efficiency of vaccines by helping the body reach a protective antibody threshold faster than with antigen alone.

    Авторское право:

    Attribution Non-Commercial (BY-NC)
    Скачайте в формате PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    623 просмотров1 страница

    GSK Flu Vaccine Production Process

    Загружено:

    Ehab Tantawy
    The document describes the international surveillance network that monitors influenza viruses in humans and animals globally. It detects important antigenic variations that allow the WHO to propose recommendations for vaccine formulations each flu season. The WHO then distributes seed strains to manufacturers like GSK to begin the 5-6 month vaccine production process. This process involves inoculating eggs, harvesting and purifying the virus, testing, filling doses, clinical trials, and regulatory approval to produce an optimized vaccine that matches the current circulating strains each year. Adjuvants can increase the efficiency of vaccines by helping the body reach a protective antibody threshold faster than with antigen alone.

    Авторское право:

    Attribution Non-Commercial (BY-NC)
    Скачайте в формате PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    из 1

    International Surveillance Network

    Detects important antigenic variations of influenza virus in humans and animals (especially birds & pigs)

    Data Summarised

    WHO distributes seed strain to vaccine manufacturers including GSK

    Start of 5-6 month vaccine production process

    Month 1

    Allows WHO to propose new recommendations for vaccine formulations for each Northern and Southern hemisphere influenza season annual vaccination and pandemics

    Vaccine composition must match global epidemiological surveillance data, so an updated vaccine formulation is developed each time

    Optimise/ establish working seed bank

    Innoculation of eggs, incubation

    Harvesting, purification

    Reagent standardisation

    Characterisation, sterility testing

    Month 2

    Month 3

    Month 3

    Month 3

    Month 3

    Filling, safety testing, release

    Clinical Trial (in Europe)

    Regulatory agency review and release

    Month 4 Month 4 Month 5

    Final vaccine = antigen + adjuvant


    Antibody titre
    With adjuvant

    Antigen only

    Month 5

    Protection threshold reached earlier


    Pulendran & Ahmed, Cell 2006; 124:849-863

    Time

    Increased efficiency of vaccines using adjuvant systems

    GSKs flu vaccine development process

    Вам также может понравиться